v3.25.2
Segment Information
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information

8. Segment Information

 

The Company operates in one reportable segment related to the development and commercialization of therapeutics. The chief operating decision maker for the Company is the Chief Executive Officer (the “CEO”). The Company’s CEO reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial performance and allocating resources. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The CEO uses aggregate net loss to allocate resources in the annual budgeting and forecasting process and also uses that measure as a basis for evaluating financial performance regularly by comparing actual results with established budgets and forecasts.

 

The accounting policies of the Company’s single segment are the same as those described in the summary of significant accounting policies within Note 3. The CEO assesses performance for the Company and decides how to allocate resources based on the aggregate net loss that is also reported on the income statement as net loss. The measure of segment assets is reported on the balance sheets as total assets.

 

The table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.

 

   2025   2024   2025   2024 
  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
   2025   2024   2025   2024 
Revenues:  $   $   $   $ 
Less:                    
Research and development   325,623    239,776    561,681    500,135 
General and administrative   370,150    345,371    808,643    859,829 
Loss from operations   (695,773)   (585,147)   (1,370,324)   (1,359,964)
Plus:                    
Interest income   35,831    83,457    77,536    173,563 
Net loss  $(659,942)  $(501,690)  $(1,292,788)  $(1,186,401)